

(19)

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 518 443 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
18.05.2005 Bulletin 2005/20

(51) Int Cl.7: **C12N 15/10**(21) Application number: **92201711.6**(22) Date of filing: **30.10.1985**

(54) **Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome**

Rekombinante Proteine von mit Lymphadenopathiesyndrom und/oder erworbenem Immunschwächesyndrom assoziierten Viren

Protéines recombinantes de virus associé au syndrome lymphadenopatique et/ou syndrome d'immunodéficience acquise

(84) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

(30) Priority: **31.10.1984 US 667501**
30.01.1985 US 696534
06.09.1985 US 773447

(43) Date of publication of application:
16.12.1992 Bulletin 1992/51

(60) Divisional application:
02077411.3 / 1 245 678

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
85307860.8 / 0 181 150

(73) Proprietor: **CHIRON CORPORATION**
Emeryville, California 94608 (US)

(72) Inventors:
• **Luciw, Paul A.**
Emeryville, California 94608 (US)
• **Dina, Dino**
Oakland, CA 94602 (US)
• **Steimer, Kathelyn**
Benicia, California 94510 (US)

- **Pescador, Ray Sanchez**
Oakland, California 94605 (US)
- **George-Nascimento, Carlos**
Danville, California 94526 (US)
- **Parkes, Deborah**
No. 104 Oakland, California 94610 (US)
- **Hallewell, Rob**
San Francisco, California 94109 (US)
- **Barr, Philip J.**
Orinda, California 94563 (US)
- **Truett, Martha**
Oakland, California 94611 (US)

(74) Representative: **Hallybone, Huw George**
Carpmaels and Ransford,
43 Bloomsbury Square
London WC1A 2RA (GB)

- (56) References cited:
- | | |
|------------------------|------------------------|
| EP-A- 0 139 216 | EP-A- 0 152 030 |
| EP-A- 0 173 529 | EP-A- 0 185 444 |
- **SCIENCE**, vol. 225, no. 4664, August 24, 1984
Washington DC J.A. LEVY et al. "Isolation of
Lymphocytopathic Retro- viruses from San
Francisco Patients with AIDS", pages 840-842

EP 0 518 443 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

Technical Field

[0001] This invention is in the field of lymphadenopathy syndrome and/or acquired immune deficiency syndrome.

Background Art

[0002] With the discovery of human T-cell lymphotropic virus-I (HTLV-I) as an infectious agent in humans, it was established that retroviruses could infect humans and could be the etiological agent of disease. After HTLV-I was established, a second retrovirus of the same family, HTLV-II was found in a hairy cell leukemia established strain. Since that time, other human retroviruses have been isolated which are associated with lymphadenopathy syndrome (LAS) and/or acquired immune deficiency syndrome (AIDS) victims. Various retroviruses have been isolated from individuals with AIDS (sometimes called HTLV-III) or LAS (sometimes called LAV). See for example, Barre-Sinoussi, et al, *Science* (1983) 220:868-871 and Montagnier, et al, Cold Spring Harbor Symposium (1984) in press; Vilmer, et al, *Lancet* (1984) 1:753, Popovic, et al, *Science* (1984) 224:497 and Gallo, et al, *Science* (1984) 224:500. A comparison of HTLV-III and LAV may be found in Feorino, et al, (1984), supra. See also, Klatzman, et al, *Science* (1984) 225: 59-62, Montagnier, et al, *ibid* (1984) 63-66, and the references cited therein for a survey of the field. A general discussion of the T-cell leukemia viruses may be found in Marx, *Science* (1984) 224:475-477. Levy, et al, *Science* (1984) 225:840-842 report the isolation of ARV (AIDS-associated retroviruses).

[0003] For the purposes of this application, these viruses (HTLV-III, LAV, and ARV) will be generically referred to as human T-cell lymphotropic retrovirus (hTLR). The hTLRs may be shown to be of the same class by being similar in their morphology, serology, reverse transcriptase optima and cytopathology, as identified in the above references. For example, the reverse transcriptase prefers Mg^{+2} , and has a pH optima of about 7.8.

Disclosure of the Invention

[0004] The invention is defined in the claims.

Brief Description of the Drawings

[0005]

Figure 1 is a restriction map of proviral DNA (ARV-2).

Figure 2 is the nucleotide sequence of ARV-2(9B). The amino acid sequences for the products of the gag, pol, and env genes are indicated. The U3, R,

and U5 regions of the LTRs are also designated. The cap site is position +1. A 3 bp inverted repeat at the ends of the LTR, the TATA box at position -29, the sequence complementary to the 3'-end of the tRNA^{lys} at position 183, and the polyadenylation signal at position 9174 are underlined. The overlines indicate the amino sequences determined from virion proteins. The nucleotides at the beginning of each line are numbered, and the amino acids at the end of each line are indicated.

Modes for Carrying Out the Invention

[0006] The hTLR DNA sequences are synthesized at least in part and may be used for expression of polypeptides which may be a precursor protein subject to further manipulation by cleavage, or a complete mature protein or fragment thereof. The smallest sequence of interest, so as to provide a sequence encoding an amino acid sequence capable of specific binding to a receptor, e.g., an immunoglobulin, will be 21 bp, usually at least 45 bp, exclusive of the initiation codon. The sequence may code for any greater portion of or the complete polypeptide, or may include flanking regions of a precursor polypeptide, so as to include portions of sequences or entire sequences coding for two or more different mature polypeptides. The sequence will usually be less than about 5 kbp, more usually less than about 3 kbp.

[0007] Sequences of particular interest having open reading frames (Figure 5) define the structural genes for the gag proteins (p16 and p25) and the env protein. It is to be understood that the above sequences may be spliced to other sequences present in the retrovirus, so that the 5'-end of the sequence may not code for the N-terminal amino acid of the expression product. The splice site may be at the 5'-terminus of the open reading frame or internal to the open reading frame. The initiation codon for the protein may not be the first codon for methionine, but may be the second or third methionine, so that employing the entire sequence indicated above may result in an extended protein. However, for the gag and env genes there will be proteolytic processing in mammalian cells, which processing may include the removal of extra amino acids.

[0008] In isolating the different domains the provirus may be digested with restriction endonucleases, the fragments electrophoresed and fragments having the proper size and duplexing with a probe, when available, are isolated, cloned in a cloning vector, and excised from the vector. The fragments may then be manipulated for expression. Superfluous nucleotides may be removed from one or both termini using Ba131 digestion. By restriction mapping convenient restriction sites may be located external or internal to the coding region. Primer repair or *in vitro* mutagenesis may be employed for defining a terminus, for insertions, deletion, point or multiple mutations, or the like, where codons may be changed, either cryptic or changing the amino acid. re-

striction sites introduced or removed, or the like, where the gene has been truncated, the lost nucleotides may be replaced using an adaptor. Adaptors are particularly useful for joining coding regions to ensure the proper reading frame.

[0009] The env domain of the hTLR genome can be obtained by digestion of the provirus with EcoRI and KpnI and purification of a 3300 base pair (bp) fragment, which fragment contains about 400 bp of 5' non-coding and about 200 bp of 3' non-coding region. Three different methionines coded for by the sequence in the 5' end of the open reading frame may serve as translational initiation sites.

[0010] Digestion of proviral sequences with SacI and EcoRV provides a fragment of about 2300 bp which contains the gag domain and a second small open reading frame towards the 3' end of the gag region. The gag domain is about 1500 bp and codes for a large precursor protein which is processed to yield proteins of about 25,000 (p25), 16,000 (p16) and 12,000 (p12) daltons. Digestion with SacI and BglII may also be used to obtain exclusively the gag domain with p12, p25 and partial p16 regions.

[0011] The hTLR DNA sequences may be labeled with isotopic or non-isotopic labels or markers and be used as DNA probes to detect the presence of native hTLR nucleotide sequences in samples suspected of containing same.

[0012] The following examples are offered by way of illustration and not by way of limitation.

EXPERIMENTAL

1. AIDS related virus-2 (ARV-2) purification and preparation of viral RNA.

[0013] HUT-78 cells infected with ARV-2 (ATCC Accession No. CRL B597, deposited on August 7, 1984) were obtained from Dr. Jay Levy, University of California, San Francisco. Cultures were grown for two weeks in RPM1 medium with 10% fetal calf serum. Cultures were centrifuged at 2 Krpm for 1 hr at 4°C using a SW-2B rotor. The pellet, containing the virus, was resuspended in 10 mM Tris-HCl, pH 7.5 on ice. The resuspended pellet was treated with 10 µg of DNase (Boehringer Mannheim) and was layered onto a linear sucrose gradient (15-50% in 10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 20 mM NaCl). The gradient was spun at 34 Krpm for 4 hr at 4°C, in SW-41 rotor. Five 2.5 ml fractions were collected and an aliquot of each was electrophoresed in a 1% agarose, 5 mM methyl mercury hydroxide gel (Bailey and Davidson, Anal Biochem (1976) 70:75-85) to determine which contained the 9 kb viral RNA. The fraction containing the viral RNA was diluted: to 10 ml in 10 mM Tris-HCl, pH 7.5, 1 mM EDTA and was centrifuged at 34 Krpm for 2 hr at 4°C. The pellet was resuspended in 20 mM Tris-HCl, pH 7.6, 10 mM EDTA, 0.1% SDS, and 200 µg/ml proteinase K. Incuba-

tion was carried out for 15 min at room temperature. The mixture was extracted with phenol and the aqueous phase was made 400 mM NaCl and precipitated with ethanol. The pellet was resuspended in water and stored at -70°C.

[0014] To purify the viral RNA from the nucleic acid pellet obtained as described above, a sample was electrophoresed in a low-melting 1% agarose gel containing 5 mM Methyl mercury hydroxide. After electrophoresis, the gel was stained with 0.1% ethidium bromide and nucleic acid bands were visualized under UV light. The region corresponding to 9 kb was cut from the gel and the agarose was melted at 70°C for 2 to 3 min in three volumes of 0.3 M NaCl, 10 mM Tris, pH 7.5, 1 mM EDTA. The mixture was extracted with an equal volume of phenol. The aqueous phase was reextracted with phenol and was precipitated with ethanol. The pellet was washed with cold 95% ethanol, air dried, resuspended in water and stored at -70°C until use. One hundred ml of culture medium yielded 0.5 to 1 µg of purified RNA.

2. Synthesis of labeled homologous viral probe.

[0015] A ³²P-labeled cDNA was made to the gel purified viral RNA using random primers (calf thymus primers) prepared as described in Maniatis, et al, A Laboratory Manual, Cold Spring Harbor, NY, 1982. The reaction mixture contained 2 µl of 0.5 M MgCl₂; 5 µl of 0.1 M dithiothreitol; 2.5 µl each of 10 mM dATP, 10 mM dGTP and 10 mM dTTP; 2.5 µl calf thymus primer (100A₂₆₀/ml); 0.5 µg viral RNA; 5 µl of actinomycin D (200 µg/ml); 10 µl of ³²P-dCTP (> 3000 Ci/mole, 1 mCi/ml) and 1 µl of AMV reverse transcriptase (17 units/µl) in a 50 µl reaction volume. The reaction was incubated for 1 hr at 37°C. The probe was purified away from free nucleotides by gel filtration using a Sephadex G50 column. The void volume was pooled, NaCl was added to a final concentration of 400 mM and carrier single-stranded DNA to 100 µg/ml, and the cDNA was precipitated with ethanol. The pellet was resuspended in water and incorporated ³²P counts were determined.

3. Detection of ARV sequences in polyA+ RNA prepared from infected HUT-78 cells.

[0016] PolyA+ RNA was prepared from HUT-78 cells infected with ARV-2, ARV-3 or ARV-4 (three different isolates from three different AIDS patients) and from uninfected HUT-78 cells. The polyA+ RNA was electrophoresed on 1% agarose gels containing 5 mM methyl mercury hydroxide (Bailey and Davidson, supra), was transferred to nitrocellulose filters, and hybridized with the homologous probe prepared as described in Section 2. Hybridizations were carried out in 50% formamide, 3 x SSC at 42°C. Washes were at 50°C in 0.2 x SSC. A 9 kbp band was present in all three samples of infected HUT-78 cells. This band was absent in polyA+ from uninfected cells.

4. Detection of ARV sequences in infected and non-infected HUT-78 cells.

[0017] High molecular weight DNA (chromosomal) was prepared from cultures of HUT-78 cells infected with ARV-2 and from non-infected HUT-78 cells following the procedure of Luciw, et al, Molec and Cell Biol (1984) 4:1260-1269. The DNA was digested with restriction enzyme(s), electrophoresed in 1% agarose gels and blotted onto nitrocellulose following the procedure described by Southern, (1975), supra. Blots were hybridized with the ³²P-labeled probe (10⁶ cpm/blot) in a mixture containing 50% formamide, 3 x SSC, 10 mM Hepes, pH 7.0, 100 µg/ml denatured carrier DNA, 100 µg/ml yeast RNA and 1 x Denhardt's for 36 hr at 42°C. Filters were washed once at room temperature in 2 x SSC and twice at 42°C in 0.2 x SSC, 0.1% SDS. Filters were air dried and exposed to X-Omat film using an intensifying screen.

[0018] The homologous ³²P-probe to ARV-2 hybridized specifically to two bands in the DNA from infected cells restricted with SacI. These bands were absent when DNA of non-infected cells was used, indicating that the probe is hybridizing specifically to infected cells presumably to the provirus integrated in the chromosomal DNA. The molecular weight of the bands is approximately 5 kb and 3 kb.

[0019] In order to determine if different enzymes would cut the proviral sequence, several other restriction digestions of the cell DNA were carried out using EcoRI, SphI or KpnI or double digestions using two of them. Southern results show specific bands hybridizing when DNA of infected cells is used. Figure 1 shows a schematic map of the positions of restriction enzyme sites in the proviral sequence, and indicates fragment sites.

5. Cloning of proviral ARV-2 DNA.

[0020] High molecular weight cell DNA from infected HUT-78 cells was prepared following the procedure of Luciw, et al, supra. The DNA was digested with EcoRI, which cuts once in the provirus, centrifuged in a sucrose gradient and fractions corresponding to 8-15 kb were pooled, dialyzed and concentrated by ethanol precipitation. The bacteriophage λ derivative cloning vector, EM-BL-4 (Karn, et al, Methods Enzymol (1983) 101:3-19) was digested to completion with a mixture of EcoRI, BamHI and Sall restriction enzymes and the DNA then deproteinized by phenol-chloroform extraction, precipitated with cold ethanol and resuspended in ligation buffer. The EMBL-4 phage DNA and EcoRI digest of cellular DNA were mixed and ligated and the resultant recombinant phage genomes packaged *in vitro*. After phage infection of λ-sensitive E. coli (DP50supF), about 500,000 phage plaques were transferred onto nitrocellulose filters, DNA was fixed and the filters were screened with a homologous ³²P-probe prepared as de-

scribed in Section 2. Eleven recombinant phage out of 500,000 phage annealed in the initial double-lift screening method (Maniatis, et al, Molecular Cloning, A Laboratory Manual, NY, 1982) to viral cDNA probe, and these were further plaque-purified and propagated in large liquid cultures for preparation of recombinant DNA. Plaque-purified phage containing ARV DNA were propagated in liquid culture in E. coli DP50supF; phage particles were harvested and banded in CsCl gradients and recombinant phage DNA was prepared by phenol extraction followed by ethanol precipitation (Maniatis, et al, supra). One µg of purified phage DNA was digested with restriction enzymes, electrophoresed on 1% agarose gels, and visualized with ethidium bromide under ultraviolet light. The DNA from these gels was transferred to nitrocellulose and annealed with viral cDNA probe.

[0021] One of the 11 phage, designated λ ARV-2(9B), was deposited at the ATCC on 25 January 1985 and given Accession No. 40158. λ ARV-2(9B) contained an insertion of full-length proviral DNA along with flanking cell sequences. Digestion of λ ARV-2(9B) DNA with SacI yielded viral DNA fragments of 3.8 kb and 5.7 kb. EcoRI digestion of λ ARV-2(9B) produced virus containing DNA species at 6.4 kb and 8.0 kb; a double digest of SacI and EcoRI gave viral DNA fragments at 3.8 kb and 5.4 kb. This pattern is consistent with that of a provirus linked to cell DNA.

[0022] In addition to λ ARV-2(9B), phage was obtained that (1) possessed the left half of the viral genome from the EcoRI site in viral DNA extending into flanking cell DNA (λARV-2(8A)) and (2) phage that had the right half of the viral genome (λARV-2(7D)) from the EcoRI site in viral DNA extending into flanking cell DNA. Bacteriophages λARV-2(7D) (right) and λARV-2(8A) (left) were deposited at the ATCC on October 26, 1984 and given Accession Nos. 40143 and 40144, respectively.

6. Polymorphism.

[0023] To measure the relatedness of independent ARV isolates, restriction enzyme digests of DNA from HUT-78 cells infected with ARV-3 and ARV-4 were analyzed with the probe made from cloned ARV-2 DNA. The SacI digest of ARV-3 DNA was similar to that of ARV-2 whereas the HindIII digests displayed different patterns. The SacI digest and the PstI digest of ARV-4 DNA differed from the corresponding digests of ARV-2 DNA. The intensity of the annealing signals obtained with ARV-3 and ARV-4 samples was much lower (about 10-fold less) than that for ARV-2 DNA probably as a result of the fact that fewer cells were infected in the ARV-3 and ARV-4 cultures. The viral-specific DNA fragments produced by SacI treatment of ARV-3 and ARV-4 DNA totaled 9.0-9.5 kbp, a value similar to that of ARV-2 and in consonance with the RNA genome sizes.

7. Sequencing of proviral DNA.

[0024] Fragments or subfragments of ARV-2 DNA from λ phage 9B were prepared and cloned into M13 according to conventional procedures (Maniatis, et al, supra). Sequencing was performed according to Sanger, et al, Proc Natl Acad Sci USA (1977) 74:5463, using the universal M13 primer or chemically synthesized primers complementary to ARV-2 sequence. The sequence is shown in Figure 2.

Claims

1. A process for the preparation of an isolated DNA polynucleotide comprising a fragment of at least 21 bp from the gag or env region of the ARV-2 sequence of Figure 2, wherein the DNA polynucleotide is chemically synthesised at least in part.
2. The process of claim 1, wherein the DNA polynucleotide comprises a fragment of at least 21 bp from the gag region of the ARV-2 sequence of Figure 2.
3. The process of claim 1, wherein the DNA polynucleotide comprises a fragment of at least 21 bp from the env region of the ARV-2 sequence of Figure 2.
4. The process of any preceding claim, wherein the DNA polynucleotide is labelled.
5. The process of claim 4, wherein the DNA polynucleotide is labelled with an isotopic label.
6. The process of claim 4, wherein the DNA polynucleotide is labelled with a non-isotopic label.

Patentansprüche

1. Verfahren zur Herstellung eines isolierten DNA-Polynucleotids, das ein Fragment von mindestens 21 bp aus der gag-Region oder der env-Region der ARV-2-Sequenz gemäß Figur 2 umfaßt, wobei das DNA-Polynucleotid mindestens teilweise chemisch synthetisiert wird.
2. Verfahren nach Anspruch 1, wobei das DNA-Polynucleotid ein Fragment von mindestens 21 bp aus der gag-Region der ARV-2-Sequenz gemäß Figur 2 umfaßt.
3. Verfahren nach Anspruch 1, wobei das DNA-Polynucleotid ein Fragment von mindestens 21 bp aus der env-Region der ARV-2-Sequenz gemäß Figur 2 umfaßt.
4. Verfahren nach einem der vorhergehenden Ansprü-

che, wobei das DNA-Polynucleotid markiert ist.

5. Verfahren nach Anspruch 4, wobei das DNA-Polynucleotid mit einem isotopischen Marker markiert ist.
6. Verfahren nach Anspruch 4, wobei das DNA-Polynucleotid mit einem nicht-isotopischen Marker markiert ist.

Revendications

1. Procédé pour la préparation d'un polynucléotide d'ADN isolé comprenant un fragment d'au moins 21 pb de la région gag ou env de la séquence ARV-2 de la figure 2, dans lequel le polynucléotide d'ADN est chimiquement synthétisé au moins en partie.
2. Procédé selon la revendication 1, dans lequel le polynucléotide d'ADN comprend un fragment d'au moins 21 pb de la région gag de la séquence ARV-2 de la figure 2.
3. Procédé selon la revendication 1, dans lequel le polynucléotide d'ADN comprend un fragment d'au moins 21 pb de la région env de la séquence ARV-2 de la figure 2.
4. Procédé selon l'une quelconque des revendications précédentes, dans lequel le polynucléotide d'ADN est marqué.
5. Procédé selon la revendication 4, dans lequel le polynucléotide d'ADN est marqué avec un marqueur isotopique.
6. Procédé selon la revendication 4, dans lequel le polynucléotide d'ADN est marqué avec un marqueur non isotopique.




FIG. 1

**G
A
G**

**P
O
L**

7

L
T
R

FIG. 2-2




FIG. 3

FIG. 4

[illegible]

FIG. 5

[illegible]

ARV GAG p16 - synthetic Parts A and B

FIG. 6

5' MetGlnArgGlyAsnPheArg^{3'} GlnGlnArgLysThrValLysCysPheAsnCysGlyLYs
 TATATGCAAGAGGTAACTTCAGGAAICAAAGAAAGACCGTTAAGTGTTCACCTGTGGTAAG
 NTATACGTTCTCCATTGAAGTCC^{5'} TAGTTCTTCTGGCAATTCACAAAGTTGACACCATTC
 3' 10 mnl1, 23 hinf1,
 63 GluGlyHisIleAlaLysAsnCysArgAlaProArgLysLysAlaCysIlePheArgCysGly
 GAAGGTCACATCGCTAAGAACTAGAGCTCCAAAGAAAGAGGCTTGTGGAGATGTGGT
 CTTCCAGGTAGCGATTCTTGACATCTCGAGGTTCTTCTCCGACACACCTCTACACCA
 76 dde1, 88 ban2 hgiA hg1J11 sac1 sdu1, 89 alu1,
 123 ArgGluGlyHisGlnMetLysAspCysThrGluArgGlnAlaAsnPheLeuGlyLYsIle
 AGAGAAGGTCACCAATGAAGGACTGTACCGAAAGACAAAGCTTCTTGGGTAAGATC
 TCTCTTCCAGTGGTTACTTCTGACATGGCTTCTGTTCGATTGAAGAACCCATTTCTAG
 129 bstE2, 131 hph, 148 rsal, 161 alu1, 178 bg111 xho2, 179
 sau3a,
 183 TrpProSerTyrLysGlyArgProGlyAsnPheLeuGlnSerArgProGluProThrAla
 TGGCCATCTTACAGGGTAGCCAGGTAACTTCTTGGCAATCCAGACCCAGAACCAACCGCT
 ACCGGTAGAATGTTCCCATCTGGTCCATTGAAGAACGTTAGGTCCTGGTCTTGGTTGGCGA
 183 ball o1r1 hae1, 184 hae111, 199 aoc1, 204 apy1 eoc11 so
 rf1,
 243 ProProGluGluSerPheArgPheGlyGluGlyLysThrPheProSerGlnLYsGlnGlu
 CCACCTGAAGAAAGTTTCAGGTTCCGGTGAAGAAAGAACCCACCCCATCTCAAAAGCAAGAA
 GGTGAATCTTTCAAAGTCCAAGCCAATCTTCTTCTGGTGGGTAGAGTTTTCGTTCTT
 249 mbo11, 267 hph, 270 mbo11,
 303 ProIleAspLysGluLeuTyrProLeuThrSerLeuArgSerLeuPheGlyAsnAspPro
 CCAATCGACACAGGAATGTATCCCATGACCTCTTGGAGATCCTTGTTCGGTAACGATCCC
 GGTAGCTGTCTTAACTAAGGTAACTGGGTAACTGGAGAACTTAGGAACAAGCCATTGCTAGGG
 307 taq1, 320 rsal, 331 mnl1, 339 xho2, 340 sau3a, 357 sau3a
 , 361 mnl1, 362 aya1 xho1,
 363 SerSerGlnOP AM
 TCGAGCCCAATGATAG
 AGCTCGGTACTATCAGCT
 363 taq1, 377 aoc1 hnd11 sal1

3908 TrpLysGluAlaThrThrThrLeuPheCysAlaSerAspAlaGargAlaIlyrAspThrGluValHisAsnValTrpAlaThrHisAlaCysValProThrAspProAsnProGlnGluVal 91
 TGGAAAGAACCACTACCACCTATTTTTGTGCATCAGATGCTAGACCATATCATACAGAGGTACATAATGTTTGGCCACACATGCTGTGTACCCACAGACCCCAACCCACAGAACTA
 6028 ValLeuGlyAsnValThrGluAsnPhoAsnMetTrpLysAsnAsnMetValGluHisMetGlnGluAspPheIleSerLeuTrpAspGlnSerLeuLysProCysValLysLeuThrPro 131
 GTATTGGGAAATGTGCAGAAAAATTTAAACATGTGGAAATTAACATGTGACAGATGTCAGAGGATATAATCAGTTTATGGGATCAAGGCTTAAGCCATGTGTAAATTTAAACCCCA
 6148 LeuCysValThrLeuAsnCysThrAspLeuGlyLysAlaThrAsnThrAsnSerSerAsnTrpLysGluValLysGlyValLysAsnCysSerPheAsnIleThrThrSerLle 171
 CTCGTGTACTTTAAATTGCACATGATTGGGGAAGCCCTACTTAATACCCTAGTAGTAATTGGAAAGAAAGAAATAAAGGCGAAATAAAGAACTGCTCTTTCAATATCACCCACAAAGCATTA
 6268 ArgAspLysIleGlnLysGluValAsnAlaLeuPheArgAsnLeuAspValValProIleAspAsnAlaSerThrThrThrAsnTrpThrAsnTrpArgLeuIleHisCysAsnArgSerVal 211
 AGAGATAGATTCAGAAAGAAAAATGECACCTTTTCTGACCTTGATGTACCAATAGATTAATGCTAGTACTTACCACATATACCAACTATAGGCTATAGGTTGATACATTTATACAGATTCAGTC
 6368 IleThrGlnAlaCysProLysValSerPheGluProIleProIleHisTrpCysThrProAlaGluPheAlaIleLeuLysCysAsnAsnLysThrPheAsnGlyLysGlyProCysThr 251
 ATTACAGGCCCTGTGCAGAGGTATCATTTTGAAGCAATTCCTCATCATATTATGTACCCCGCTGGTTTTCGGATCTTAAAGTGTATAATAAAGCTTCAATGGAAAAAGACCATGTATACA
 6508 AsnValSerThrValGlnCysThrHisGlyIleArgProIleValSerThrGlnLeuLeuAsnGlySerLeuAlaGluGluValValIleArgSerAspAsnPheThrAsnAsn 291
 AATGTACAGACATGACATGTACACATGGAATAGGCCAATAGTGTCACTCACTGCTGTAAATGGCAGCTACAGAAAGAGGTAGTAAATAGATCTGACAAATTCACAGAACTA
 6628 AlaLysThrIleIleValGlnLeuAsnGluSerValAlaIleAsnCysThrArgProAsnAsnAsnThrArgLysSerIleTrpIleGlyProGlyArgAlaPheHisThrThrGlyArg 331
 GCTAAACCATTAATAGTACGCTGAATGAATCTGTAGCAATTAACCTGTACAGACCCACCAACATACAGAAAGAGTATCTATATAGGACCAAGGAGAGCATTCATACAGACAGAGAGA
 6748 IleIleGlyAspIleArgLysAlaHisCysAsnIleSerArgAlaGlnTrpAsnAsnThrLeuGluGlnIleValLysLysLeuArgGluGlnPheGlnHisThrIleValPhe 371
 ATAATAGGAGATATAGAAAGACACATTTAACAATAGTACGACCAATGGAATTAACACTTTAGACAGATAGTTAAAGAAATTAAGAGACAAATTTGGGAATAATAAAGCAATAGTCTTT
 6868 AsnGlnSerSerGlyGlyAspProGluIleValMetHisSerPhaAsnCysArgGlyGluPhePheTrpCysAsnThrThrGlnLeuPheAsnAsnThrTrpArgLeuLeuHisHisThrGlu 411
 AATCAATCTCTAGGAGGAGGACCCAGAAATTTGAATGCAACATTTTAATTTGAGAGGGGAATTTTCTACTTAATACACACAACTGTTTAATAATATACATGAGAGTTAAACACACTGAA
 6988 GlyThrLysGlyAsnAspThrIleIleLeuProCysArgIleLysGlnIleIleAsnMetTrpGlnGluValGlyLysAlaMetTrpAlaProProIleGlyGlyGlnIleSerCysArg 451
 GGAACTAAGCAATGACACAAATCATACTCCATGTAGAAATAAACAATATATAACATGTGACAGGAAATGAGAAAGCAATATGTACCCCTCCCATTTGAGAGCAAAATAGTGTGTCA
 7108 SerAsnIleThrGluLeuLeuThrArgAspGlyGlyThrAspValThrAsnAspThrGluValPheArgProGlyGlyGlyAsnMetArgAspAsnTrpArgSerGluLeuTrpLys 491
 TCAATATATACAGCCCTGCTATTAAACAGAGATGTGTATACAAATATACACTAATACACCCAGGTCTTCAGACCTTGGAGGAGGAGATATAGGGAGCAATTTGAGAGCACTGAATATATATAA

FIG. 7

FIG. 8-1

Nucleotide
Positions
Relative to
Figure 2

MetIleAspLysAlaGlnGluGluHisGluLysTyrHisSerAsnTrp
1 AGGXAACAG:::ATGAT:GA:AAGGCACAGAGAACATGAGAAATATCACAGTAATTGG
TCCXTTGTCT:::TACTA:CT:TTCCGTGTTCTTCTGTACTCTTTATAGTGTCAATTAACC

32 mbo11, 38 nla111,
3820 62 ArgAlaMetAlaSerAspPheAsnLeuProProValValAlaLysGluIleValAlaSer
AGAGCCATGCTAGTGAATTTAACCTGCCACCTGTAGTAGCAAAAGAAAAGTAGCCAGC
TCTCGGTACCGATCACTAAATTTGGACGGTGGACATCATCGTTTTCTTTATCATCGGTCTG

66 nco1, 67 nla111, 118 nspB11 pvu11, 119 alu1,
3880 122 CysAspLysCysGlnLeuLysGlyGluAlaMetHisGlyGlnValAspCysSerProGly
TGTGATAAATGTCAAGCTAAAGGAGAGCCATGCAATGGACAAAGTAGACTGTAGTCCAGGA
ACACTATTACAGTCAATTTTCTCTTCCGTACGTACCTGTTCTATCTGACATCAAGTCTCT

135 alu1, 151 nla111, 152 nsi1 ava3, 155 nla111, 164 acc1, 1
76 apy1 bstX1 ecor11 scrF1,
3940 182 IleTrpGlnLeuAspCysThrHisLeuGluGlyLysIleIleLeuValAlaValHisVal
ATATGGCAACTAGATTGTACACATCTAGAAAGAAAAATATCTCTGGTAGCAGTTTATGTA
TATACCGTTGATCTAATCATGTGTAGATCTTCTCTTTTAAATAGGACCATCGTCAAGTACAT

198 rsa1, 205 xba1, 223 apy1 ecor11 scrF1, 236 nla111,
4000 242 AlaSerGlyTyrIleGluAlaGluValIleProAlaGluThrGlyGlnGluThrAlaTyr
GCCAGTGGATATATAGAAAGCAGAAAGTTATTCAGCAGAGACAGGGCAGGAAACAGCATAT
CGGTCACTATATATCTTCTCTCAATAAGGTCGTCTCTGTCCCGTCTTTGTCTGTATA

263 xmn1,
4060 302 PheLeuLeuLysLeuAlaGlyArgTrpProValLysThrIleHisThrAspAsnGlySer
TTTCTCTTAAATAGCAGGAAGATGGCCAGTAAACCAATACATACAGACAATGGCAGC
AAAGAGAATTTTAAATCGTCTTCTCGGTCAATTTTGTATGTATGTCTGTACCTGTCG

321 mbo11, 326 bal1 cfr1 hae1, 327 hae111, 357 bbv1 fnu4h1,
4120 362 AsnPheThrSerThrThrValLysAlaAlaCysTrpTrpAlaGlyIleLysGlnGluPhe
AATTTCCAGTACTACGGTTAAGGCTCGCTTGTGTGTGGCAGGGATCAAGCAGGAATTT
TTAAAGTGGTCTATGATGCCAATTTCTTCCGGCAGCAACCAACCCGTCCTTGTCTCTTAAAG

366 hph, 371 sca1, 372 rsa1, 385 hae111, 386 fnu4h1 nsp11, 4
05 bin1, 406 dpn1 sau3a,
4180 422 GlyIleProTyrAsnProGlnSerGlnGlyValValGluSerMetAsnAsnGluLeuLys
GGCATTCCCTACAATCCCCAAGTCAAGGAGTAGTAGAATCTATGAATAATGAATTAAG
CCGTAAAGGATGTTAGGGGTTTCAGTTCTCTCATCATCTTAGATACCTATTACTTAATTTCT

423 bsm1, 458 hinf1,
4240 482 LysIleIleGlyGlnValArgAspGlnAlaGluHisLeuLysThrAlaValGlnMetAla
AAAATTATAGGACAGGTAAGAGATCAGGCTGAACACCTTAAGACAGCAGTACAATGGCA
TTTTAATATCTGTCTCATTCTCTAGTCCGACTTGTGGAAATCTGTCTCATGTTTACCGT

503 dpn1 sau3a, 518 af111, 530 rsa1,
4300 542 ValPheIleHisAsnPheLysArgLysGlyGlyIleGlyGlyTyrSerAlaGlyGluArg
GTATTCATCCACAATTTTAAAGAAAGAGGAGATTGGGGATACAGTGCAGGGAGAAAGA
CATAAGTAGGTGTTAAATTTTCTTTTCCCCCTAACCCCTATGTCACGTCCCTTTCT

547 fok1, 557 aha111,
4360 602 IleValAspIleIleAlaThrAspIleGlnThrLysGluLeuGlnLysGlnIleThrLys
ATAGTAGACATAATAGCAACAGATACAACTAAAGAACTACAAAGCAAAATTACAAA
TATCATCTGTATTATCGTTGTCTGTATGTTGATTTCTTGTATGTTTCTGTTTAATGTTT

605 acc1,
4420 662 IleGlnAsnPheArgValTyrTyrArgAspAsnLysAspProLeuTrpLysGlyProAla
ATTCAAAATTTTCTGGTTTATTACAGGGACAACAAAGATCCCTTTGGAAAGGACAGCA
TAAGTTTAAAGCCCAATAATGTCCCTGTTGTTTCTAGGGGAAACCTTTCTGGTCTG

697 xho2, 698 dpn1 sau3a, 713 asu1 ava2,

4480	722	<p> LysLeuLeuTcPLysGlyGluGlyAlaValValIleGlnAspAsnSerAspIleLysVal AAGCTTCTCTGGAAAGGTYGAAGGGGCGAGTAGTAATACAGGAAATAGTGGATATAAGTA TCGAAGAGAGACCTTCCACTCCCCGTCATCATTAATGTTCTATTATCACGTGTATTTTCAT 722 hind11, 723 alu1, 737 hph, </p>
4540	782	<p> ValProArgAcGlyValAlaLysIleIleArgAspTyrGlyLysGlnMetAlaGlyAspAsp GTGCCAAGAAAGAAAGCAAAATCATTAGGGGATATAGGAAACAGATCCGAGGGTGAAGAT CACGGTCTCTCTTTTCGTTTCTAGTAATCCCTAAATACCTTTGTCTACCGTCCACTACTA 789 mbo11, 833 hph, </p>
4600	842	<p> CysValAlaSerArgGlnAspGluAspAM TGTGTGGCAAGTAGACAGGATGAGGATTAGTCCAGCGGAATCTTTAGTAAACACCC ACACACCGTTCTATCTGTCTTACCTAATCAGCTGCCCTTAGGAAATCATTTGTGG 852 aat1, 859 fck1, 863 mnl1, 871 aat1 hind11 sal1, 872 taq1 , 878 ecor1, </p>

FIG. 8-2